฿16.14
-฿0.28(-1.70%)
data.updated
v2.stock.overview v2.daily.trading v2.range.52w
key.stats
yesterday.close฿16.37
market.size฿2.13B
volume.trade823.22K
pe.ratio7.46
div.yield0.00%
diluted.eps2.13
net.income฿287.20M
revenue฿283.05M
earnings.date2026-05-11
eps.estimate0.18
rev.estimate฿76.97M
shares.out130.29M
beta1.523
about.stock
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
sectorHealthcare
industryBiotechnology
ceoKevin C. Tang
headquartersEdmonton,BC,CA
employees128.00
avg.revenue฿2.21M
income.per.emp฿2.24M
stock.faq
stock.price
x
current.stats
52w.range.q
x
pe.ratio.q
x
market.cap.q
x
eps.recent.q
x
buy.sell.q
x
price.factors
x
buy.how
x
risk.warn
risk.notice
disclaimer2
risk.disclosure
กระทู้ร้อนแรงเกี่ยวกับ Aurinia Pharmaceuticals (AUPH)
ImpermanentPhilosopher
0
0
0
0